Foreign medicines continue to arrive in Russia, and the recent changes are minor in scope, often reflecting the challenges faced by manufacturers themselves. This assessment comes from Dmitry Galkin, head of the department for the development of the pharmaceutical and medical industry at the Ministry of Industry and Trade. Interfax.
“Fortunately, the majority of foreign medicines keep making their way into the country. During a discussion in the Federation Council about import substitution in pharmaceuticals, Galkin noted that all manufacturing companies remain in operation and active,” he stated.
He explained that occasional shifts in the variety of drugs available on the Russian market are linked to broader economic pressures or direct issues faced by individual producers, rather than a sweeping disruption of supply.
Galkin emphasized that the pharmaceutical sector is not driven by political considerations, yet in Russia, risks are acknowledged and proactive plans are developed to handle unforeseen circumstances and ensure continuity of access to essential drugs.
Earlier, Roszdravnadzor reported an uptick in prices for medicines deemed vital for public health.
There was also notice of shortages in certain anti-arthritis medications in Russian pharmacies around early December.
Back in October, the Ministry of Industry and Trade did not support proposals to import medicines from India, indicating a preference for reinforcing domestic production and supply chains.
Additionally, the Security Council Secretary highlighted concerns tied to parallel imports, acknowledging gaps that could affect drug availability and pricing.